Loading publications…
The last 5 uploaded publications
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han (2016). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), pp. 56-66, DOI: 10.1016/s0140-6736(16)32453-9.
Article145 days agoPrognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Jordi Bruix, Ann‐Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Josep M. Llovet (2017). Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. Journal of Hepatology, 67(5), pp. 999-1008, DOI: 10.1016/j.jhep.2017.06.026.
Article145 days agoLenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone I. Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer J. Knox, Janine M. Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis J. Villanueva-Rivera, Patricio Yanez Weber, Marcelo Garrido, Gonzalo Pizarro, Nicolás Yáñez, Ruocai Xu, Shuangyan Ou, Zhenggang Ren, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Shukui Qin, Juxiang Xiao, Weijia Fang, Xin Wang, Yuxian Bai, Xiaohong Chen, Yan Dong, Hong Zhao, Jieer Ying, Carlos Bonilla, Olga Urrego, Ángela R. Zambrano, Mauricio Lema, Juan Carlos Restrepo, Andrés F. Cardona, Sandra Franco Millan, Madiedo Oscar, Víctor Ramos, Philippe Merle, Samuel Lesourd, Julien Edeline, Jean‐Pierre Bronowicki, Marc Bourlière, Stéphane Cattan, Mohamed Bouattour, Laurent Mineur, Hélène Regnault, Barbara Dauvois, Kornelius Schulze, Gunnar Folprecht, Andreas Geier, Oliver Waidmann, Fabian Finkelmeier, Marino Venerito, Marie‐Luise Berres, Thomas Berg, Christian M. Lange, Hartmut Schmidt, Dirk Waldschmidt, Michael Bitzer, Ray McDermott, Austin G. Duffy, Gianluca Masi, Vittorina Zagonel, Giuseppe Tonini, Fabio Piscaglia, Stefania Gori, Mimma Rizzo, Elisa Biscaldi (2023). Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 24(12), pp. 1399-1410, DOI: 10.1016/s1470-2045(23)00469-2.
Article145 days agoLenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
Josep M. Llovet, Masatoshi Kudo, Ann‐Lii Cheng, Richard S. Finn, Peter R. Galle, Shuichi Kaneko, Tim Meyer, Shukui Qin, Corina E. Dutcus, Erluo Chen, Leonid Dubrovsky, Andrew X. Zhu (2019). Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. Journal of Clinical Oncology, 37(15_suppl), pp. TPS4152-TPS4152, DOI: 10.1200/jco.2019.37.15_suppl.tps4152.
Article145 days agoMilestones in the pathogenesis and management of primary liver cancer
Jean‐Charles Nault, Ann‐Lii Cheng, Bruno Sangro, Josep M. Llovet (2020). Milestones in the pathogenesis and management of primary liver cancer. Journal of Hepatology, 72(2), pp. 209-214, DOI: 10.1016/j.jhep.2019.11.006.
Editorial material145 days ago